Bayer Schering Pharma of Germany will invest $129 million to build a global R&D center located in Beijing. The investment will take place over five years. For Bayer Schering, China is the third largest market, and the company already has already located R&D centers in the US and Europe, its two markets that are larger than China. The Beijing center will be very mindful of the clinical profile and medical needs of Asian patients, though the center is not exclusively devoted to the Asian market. More details...

Stock Symbol: (Frankfurt: SCH)